A review of linezolid: the first oxazolidinone antibiotic

References

• Anon. NNIS system report data, January 1992 to June 2002. Am. J Infect. Control 30, 458–475 (2002).
   PubMed Web of Science ®Google Scholar
• Anon. MMWR Morb. Mortal. Wkly Rep. 51(40), 902 (2002).
   Google Scholar
• Anon. MMWR Morb. Mortal. Wkly Rep. 51(26), 565–567 (2002).
   PubMedGoogle Scholar
• Fridkin SK, Hageman J, McDougal LK, et al. Vancomycin-intermediate Staphylococcus aureumpidemiology study group. Clin. Infect. Dis. 36, 429–439 (2003).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Devine JG, Yogev R, et al Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. 22, 677–686 (2003).
   Google Scholar
• Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect. Dis. J.22(9), S193—S200 (2003).
   Google Scholar
• Pharmacia & Upjohn. Zyvox® (linezolid) package insert. Pharmacia & Upjohn, MI, USA (2002).
   Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents ChernotheE 42, 3251–3255 (1998).
   PubMed Web of Science ®Google Scholar
• Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyltransferase center. Mo/. Biol. 294, 93–101 (1999).
   PubMed Web of Science ®Google Scholar
• Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn MicrobioL Infect. Dis. 43, 75–83 (2002).
   PubMed Web of Science ®Google Scholar
• •Demonstrates the antimicrobial activity of linezolid in a multi-center evaluation in North America.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. NCCLS document M 100—S12. National Committee for Clinical Laboratory Standards, PA, USA (2002).
   Google Scholar
• Behra-Miellet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int. J Antimicrob. Agents 22, 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents ChernotheE 45, 764–767 (2001).
   PubMed Web of Science ®Google Scholar
• Sweeney MT, Zurenko GE. ha vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, EnterococcL Pneurnococci and selected Gram-negative organisms. Antimicrob. Agents Chernother 47, 1902–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, Crist CJ, Mann LB. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Di& 33, 1433–1434 (2001).
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Boswell FJ, Ashby JP The in vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob. Chernother. 42, 721–728 (1998).
   PubMed Web of Science ®Google Scholar
• Andes D, Van Ogtrop ML, Craig WA. Pharmacodynamic activity of a new oxazolidinone linezolid in an animal infection model. Am. Soc. Microbiol. (1998) (Abstract 9).
   Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. j Antimicrob. Chernother 51 (Suppl. S2), 1117—ii25 (2003).
   Google Scholar
• Bassetti M, Farrel PA, Callan DA, Tonal JE, Dembry LM. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int. J Antimicrob. Agents. 21, 593–594 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP, Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179 (2001).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).
   Google Scholar
• Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect. Dis. 186, 1603–1607 (2002).
   PubMed Web of Science ®Google Scholar
• Pawsey SD, Daley-Yates PT, Wajszczuk, et al. U-1007666 safety, toleration and pharmacokinetics after oral and intravenous administration. Federation for the Societies for European Chemotherapy and Infection (1996) (Abstract F151).
   Google Scholar
• Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chernother. 45, 1843–1846 (2001).
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob. Chernother. 50, 73–77 (2002).
   PubMed Web of Science ®Google Scholar
• Conte J, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chernother. 46, 1475–1480 (2002).
   PubMed Web of Science ®Google Scholar
• •600 mg intravenous linezolid was administered to healthy individuals and the epithelial cell lining fluid concentrations for S. pneumonia, Enterococcusspp. and S. aureus were observed.
   Google Scholar
• Shaikh ZH, Peloquin CA, Ericsson CD. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Scand. J Infect. Dis. 33, 375–379 (2001).
   PubMedGoogle Scholar
• Weinkers LC, et al. h7 vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of the major human metabolite, PNU-14258. Am. Soc. MicrobioL (1999) (Abstract 11).
   Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase ffl studies. Antirnicrob. Agents Chernother. 47, 1824–1831 (2003).
   PubMed Web of Science ®Google Scholar
• Kinan A, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Cilia. Infect. Dis. 34, 695–698 (2002).
   PubMed Web of Science ®Google Scholar
• Orrick JJ, Johns T, Janelle J, Ramphall R. Thrombocytopenia secondary to linezolid administration: What is the risk? Clin. Infect. Dis. 35, 348–349 (2002).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharrnacotherapy21, 1010–1013 (2001).
   Google Scholar
• Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barite AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37, 517–520 (2003).
   PubMed Web of Science ®Google Scholar
• Young NS (Ed.). Bone Marrow Failure Syndromes. WB Saunders, PA, USA (2000).
   Google Scholar
• Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin. Infect. Dis. 37, 1389–1391 (2003).
   PubMed Web of Science ®Google Scholar
• Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins, NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to orally tyramine. Clin. PharmacoL 41, 552–562 (2001).
   Google Scholar
• Walker SE, Shulman KI, Tailor SA, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J. Clin. RychopharmacoL 16, 383–388 (1996).
   PubMed Web of Science ®Google Scholar
• Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of co. administration with pseudoephedrine HC1, phenylpropanolamine HC1 and dextromethorphan HBE J. Cilia. PharmacoL 41, 563–572 (2001).
   PubMed Web of Science ®Google Scholar
• Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin. Infect. Dis. 34, 1651–1652 (2002).
   PubMed Web of Science ®Google Scholar
• Bernard L, Stern R, Lew D, Hoffmeyer Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin. Infect. Dis. 36, 1197 (2003).
   PubMed Web of Science ®Google Scholar
• Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin re-uptake inhibitors in bone marrow transplant recipients. Clin. Infect. Dis. 1, 37 (2003).
   Google Scholar
• Pharmacia & Upjohn Company. Briefing package for NDAs 21–130, 21–131, 21–132. Antfinfective Drugs Advisory Committee Meeting review of the US Food and Drug Administration (2000).
   Google Scholar
• Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antirnicrob. Agents Chernother. 44, 3408–3413 (2000).
   PubMed Web of Science ®Google Scholar
• •• Evaluated the safety and efficacy of linezolid administered intravenously or orally as compared to oxacillin followed by dicloxacillin in treating skin and soft tissue infections.
   Google Scholar
• Weigelt JA, Itani KM, Lau WK, Somero MS. Linezolid versus vancomycin in the treatment of complicated skin and soft tissue infections (OSSTI): clinically significant outcome differences. IDSA Annual Meeting (2003) (Abstract 314).
   Google Scholar
• Lipsky BA, Itani K, Norden C, Linezolid diabetic foot infections study group. Treating diabetic foot infections: a randomized, multicenter, open-label trial of linezolid vs. ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38, 17–24 (2004).
   PubMed Web of Science ®Google Scholar
• •• This study evaluated the efficacy of linezolid versus aminopenicillinifl-lactamase inhibitors for treating diabetic foot infections.
   Google Scholar
• San Pedro GS, Cammarata SK, Oliphant TH, Todisco T Linezolid community-acquired pneumonia study group. Linezolid vs. ceftriaxonekefpodoxime in patients hospitalized for the treatment of Streptococcus pneurnoniae pneumonia. Scand. J. Infect. Dis. 34, 720–728 (2002).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata S, Wunderlink R. Linezolid nosocomial pneumonia study group. Linezolid (PNU-10076) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32, 402–412 (2001).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Cilia. Ther. 25, 980–992 (2003).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid versus vancomyicn: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124, 1 78 9–1 79 7 (2003).
   Google Scholar
• •• Analyzed two previously published studies of patients with MRSA nosocomial pneumonia infections, and utilized Kaplan-Meier survival rates to compare linezolid to vancomycin therapies.
   Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34, 1481–90 (2002).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Di Biagio A, Cenderello G, et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J. Infect. 43, 148–149 (2001).
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36, 159–168 (2003).
   PubMed Web of Science ®Google Scholar
• •Evaluated the utilization of linezolid in treating adult patients with documented VRE infections.
   Google Scholar
• Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes from linezolid from an ongoing compassionate use trial of patients with significant, resistant Gram-positive infections. Interscience Con. Antimicrob. Agents Chernother (1999) (Abstract 1098).
   Google Scholar